These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37818589)

  • 1. Sustained metabolic benefits of ΔTRTX-Ac1, a tarantula venom-derived peptide, when administered together with exenatide in high-fat fed mice.
    Coulter-Parkhill A; Tanday N; Cobice D; McLaughlin CM; McClean S; Gault VA; Irwin N
    Diabetes Obes Metab; 2024 Jan; 26(1):329-338. PubMed ID: 37818589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.
    Coulter-Parkhill A; Dobbin S; Tanday N; Gault VA; McClean S; Irwin N
    Biochem Pharmacol; 2023 Jun; 212():115544. PubMed ID: 37044298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function.
    Coulter-Parkhill A; Gault VA; McClean S; Irwin N
    Eur J Pharmacol; 2023 Sep; 954():175855. PubMed ID: 37391009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
    Hasib A; Khan D; Craig SL; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2019 Dec; 865():172733. PubMed ID: 31614140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.
    Franklin ZJ; Lafferty RA; Flatt PR; McShane LM; O'Harte FPM; Irwin N
    Biochimie; 2022 Aug; 199():60-67. PubMed ID: 35439540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
    Tanday N; Lafferty RA; Flatt PR; Irwin N
    Diabetes Obes Metab; 2022 Dec; 24(12):2353-2363. PubMed ID: 35848461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
    Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
    PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
    Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
    Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
    Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
    Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
    Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N
    Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
    Tatarkiewicz K; Belanger P; Gu G; Parkes D; Roy D
    Diabetes Obes Metab; 2013 May; 15(5):417-26. PubMed ID: 23163898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.